Stanley R. Riddell
Fred Hutchinson Cancer Center
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
CAR-T cell therapy research
Strong evidence · 11 supporting papers · latest 2026
Multiple Myeloma Research and Treatments
Strong evidence · 7 supporting papers · latest 2026
Renal Transplantation Outcomes and Treatments
Solid evidence · 1 supporting paper · latest 2025
Cancer Genomics and Diagnostics
Solid evidence · 2 supporting papers · latest 2026
Hematopoietic Stem Cell Transplantation
Solid evidence · 2 supporting papers · latest 2026
Immune Cell Function and Interaction
Solid evidence · 1 supporting paper · latest 2026
Immunotherapy and Immune Responses
Solid evidence · 4 supporting papers · latest 2026
Monoclonal and Polyclonal Antibodies Research
Solid evidence · 2 supporting papers · latest 2026
Publications (15)
Quantifying HLA transcripts by genotype in chimeric mixtures at single-cell resolution
2025DOIPMID 41000947
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination
2026DOI
Peripheral HLA-DR+ Neutrophils, CD163+ Monocytes and Inflammatory Serum Cytokines Coincide with Severe Immune Effector Cell-Associated Neurotoxicity at Peak Toxicity Onset in CD19 CAR T cell Therapy
2026DOI
A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma
2026DOIPMID 42389828
Coordinated expansion of CD163⁺ monocytes and immature CD177⁺ neutrophils marks severe neurotoxicity after CD19 CAR T cell therapy
2026DOIPMID 42465399
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination
2026DOIPMID 41963322
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials
2025DOIPMID 40930223
Myeloma and therapy reshape the bone marrow niche to durably constrain immune reconstitution and vaccine responsiveness
2026DOI
Multiple myeloma and therapy reshape the bone marrow niche to durably constrain immune reconstitution and vaccine responsiveness
2026DOI
Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts
2026DOIPMID 41659920
Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma
2025DOI
Enhanced BCMA Antigen Density Increases Trogocytosis and Attenuates CAR T cell Function
2026DOIPMID 42523297
Nivolumab following CAR-T failure in multiple myeloma and non-Hodgkin lymphoma: results of a phase 2 study
2025DOI
Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.
2025DOI
Abstract 6815: Biologic processes enriched in the primary tumors of invasive breast cancer patients with disseminated tumor cells
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Fred Hutchinson Cancer Center
Source: OpenAlex · retrieved 2026-09-29